<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment and outcomes of congenital hyperinsulinism
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment and outcomes of congenital hyperinsulinism
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment and outcomes of congenital hyperinsulinism
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Diva D De Leon-Crutchlow, MD, MSCE
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Katherine Lord, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph I Wolfsdorf, MD, BCh
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 03, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Congenital hyperinsulinism (HI) is the leading cause of persistent hypoglycemia in infants and children. Dysregulated insulin secretion leads to severe recurrent hypoglycemia and suppresses production of ketone bodies, a crucial alternative fuel for the brain. These metabolic abnormalities result in a high risk of brain damage and subsequent neurologic sequelae, such as development delays and epilepsy [
         <a href="#rid1">
          1
         </a>
         ]. The goal of HI management is to prevent hypoglycemia through the use of appropriate medical therapy, or surgical intervention in the case of the focal form. Genetic testing and advanced imaging techniques have allowed for more tailored approaches to treatment, resulting in improved outcomes.
        </p>
        <p>
         An overview of the treatment, complications, and long-term outcomes of HI will be presented here. The pathophysiology, genetics, clinical features, and diagnosis of HI are discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5810.html" rel="external">
          "Pathogenesis, clinical presentation, and diagnosis of congenital hyperinsulinism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          TREATMENT GOALS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The main principles of HI management are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rapid correction of hypoglycemia, followed by measures to maintain plasma glucose within the normal range (plasma glucose &gt;70 mg/dL).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initiation of optimal therapy for the specific HI type (presumed or confirmed), while allowing normal feeding behavior for patient age.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prevention or mitigation of brain damage by maintaining euglycemia, with early identification of any deficits through periodic developmental assessments to permit appropriate therapies or educational interventions  (
         <a class="graphic graphic_table graphicRef128297" href="/z/d/graphic/128297.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1858082816">
         <span class="h1">
          ACUTE TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Administer an intravenous (IV) dextrose bolus (2 mL/kg of 10% dextrose [0.2 g dextrose per kg of body weight]) to rapidly bring plasma glucose into the normal range. If IV access cannot be readily obtained, 1 mg of
         <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">
          glucagon
         </a>
         can be given intramuscularly to rapidly increase the glucose in children with known HI. A sample of blood should be taken for diagnostic testing ("critical sample")
         <strong>
          before
         </strong>
         administering the dextrose bolus, provided that it does not delay treatment.
        </p>
        <p>
         Following the initial dextrose bolus, an
         <a class="drug drug_pediatric" data-topicid="13222" href="/z/d/drug information/13222.html" rel="external">
          IV dextrose
         </a>
         infusion should be started at a glucose infusion rate (GIR) of 5 to 6 mg/kg/min and titrated up to achieve a plasma glucose &gt;70 mg/dL. The initial titration should be performed rapidly (eg, measuring plasma glucose every 30 to 60 minutes and adjusting the GIR accordingly) until a stable plasma glucose within the normal range is established. Infants with HI often require GIRs &gt;10 mg/kg/min and some require GIRs of 20 to 30 mg/kg/min to maintain euglycemia. However, it is important to note that some infants with hyperinsulinism have lower GIR requirements (&lt;10 mg/kg/min). To minimize fluid overload, higher concentrations of dextrose (20 to 50%) can be administered via a central venous catheter.
        </p>
        <p>
         A concurrent continuous IV infusion of
         <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">
          glucagon
         </a>
         (eg, 1 mg/day) can be considered if the GIR is high and fluid overload is a concern, while the child awaits definitive treatment [
         <a href="#rid2">
          2
         </a>
         ]. It can lower GIR requirements and prevent or mitigate fluid overload. Due to its poor solubility, glucagon must be administered through IV and therefore is not a long-term management option. New formulations with improved solubility are in development, which will allow for subcutaneous administration via an insulin pump [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Additional details on the acute treatment of hypoglycemia are provided in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/5805.html" rel="external">
          "Approach to hypoglycemia in infants and children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2461758035">
         <span class="h1">
          INITIAL MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H1611479625">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         A diagnostic evaluation for causes of hypoglycemia should be undertaken once the child is clinically stable. Key steps are confirmation of HI by tests performed on the "critical sample" collected during an episode of hypoglycemia  (
         <a class="graphic graphic_table graphicRef128060" href="/z/d/graphic/128060.html" rel="external">
          table 2
         </a>
         ), followed by a trial of
         <a class="drug drug_pediatric" data-topicid="13224" href="/z/d/drug information/13224.html" rel="external">
          diazoxide
         </a>
         , and identifying the type of HI based on the response to diazoxide and genetic testing results  (
         <a class="graphic graphic_algorithm graphicRef128425" href="/z/d/graphic/128425.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5805.html" rel="external">
          "Approach to hypoglycemia in infants and children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5810.html" rel="external">
          "Pathogenesis, clinical presentation, and diagnosis of congenital hyperinsulinism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1384823798">
         <span class="h2">
          Nutrition
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infants should be allowed to feed on demand and/or receive appropriate feeding volumes based on age and weight. Similarly, older children should be maintained on an age-appropriate diet. Nutritional modifications, such as fortified feeds, alone are not sufficient to treat HI. Moreover, forced feeds or continuous feedings lead to poor feeding skills and long-term feeding aversion [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2793628037">
         <span class="h2">
          Diazoxide trial
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once the diagnosis of HI has been made, the critical next step is to determine if the child responds to
         <a class="drug drug_pediatric" data-topicid="13224" href="/z/d/drug information/13224.html" rel="external">
          diazoxide
         </a>
         (
         <a class="graphic graphic_algorithm graphicRef128425" href="/z/d/graphic/128425.html" rel="external">
          algorithm 1
         </a>
         ). This trial establishes therapeutic benefit and also provides important phenotype information. Diazoxide is the first-line agent for the treatment of HI and is the only oral agent available. An agonist of the sulfonylurea receptor (SUR-1), it opens the adenosine triphosphate-sensitive potassium (K
         <sub>
          ATP
         </sub>
         ) channel and inhibits insulin secretion [
         <a href="#rid5">
          5
         </a>
         ]. The majority of children with K
         <sub>
          ATP
         </sub>
         -HI will not respond to diazoxide, because they do not express SUR-1 on the beta cell plasma membrane.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initiation
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="13224" href="/z/d/drug information/13224.html" rel="external">
          Diazoxide
         </a>
         is initiated at 5 mg/kg/day (or 10 mg/kg/day in more severe cases, such as those requiring a glucose infusion rate [GIR] &gt;10 mg/kg/min). If hypoglycemia persists after two to three days on the initial dose, diazoxide should be titrated up to a maximum of 15 mg/kg/day (maximum dose 500 mg twice daily for an adult).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Test for
         </strong>
         <a class="drug drug_pediatric" data-topicid="13224" href="/z/d/drug information/13224.html" rel="external">
          diazoxide
         </a>
         <strong>
          responsiveness
         </strong>
         – After five days on a stable dose, a carefully monitored fast ("safety fast") should be performed to determine whether the diazoxide treatment has corrected the cardinal feature of HI, which is hypoketotic hypoglycemia during fasting  (
         <a class="graphic graphic_algorithm graphicRef128425" href="/z/d/graphic/128425.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <strong>
          Safety fast protocol:
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Start of test – The fast typically begins after dinner, bedtime snack, or evening feed
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Monitoring – Obtain bedside plasma glucose and beta-hydroxybutyrate (BOHB), if available, every three hours while plasma glucose is &gt;70 mg/dL (3.9 mmol/L)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Endpoint of test – The test should be ended when any of the following conditions are met:
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Plasma glucose is &lt;70 mg/dL (3.9 mmol/L)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Bedside plasma BOHB is &gt;2.5 mmol/L
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A specific duration has been reached (12 hours if &lt;1 year old, 18 hours if &gt;1 year old)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Child develops symptoms of neuroglycopenia
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interpretation
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="13224" href="/z/d/drug information/13224.html" rel="external">
          Diazoxide
         </a>
         responsiveness is defined by the following glucose and/or ketone response during the safety fast [
         <a href="#rid6">
          6
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Plasma glucose maintained ≥70 mg/dL,
         <strong>
          or
         </strong>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         BOHB rises to &gt;2 mmol/L before plasma glucose drops below 50 to 60 mg/dL
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Subsequent medical therapy is guided by the results of this trial, as outlined in the next section.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1373346260">
         <span class="h1">
          DIAZOXIDE-RESPONSIVE PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children who respond to
         <a class="drug drug_pediatric" data-topicid="13224" href="/z/d/drug information/13224.html" rel="external">
          diazoxide
         </a>
         may be safely discharged on diazoxide, with home glucose monitoring  (
         <a class="graphic graphic_algorithm graphicRef128425" href="/z/d/graphic/128425.html" rel="external">
          algorithm 1
         </a>
         ). Comprehensive HI genetic testing should be considered to assist with prognosis and guide duration of therapy as well as future family planning. The main side effect seen with diazoxide is fluid overload, which can result in respiratory and cardiac complications in younger patients [
         <a href="#rid7">
          7
         </a>
         ]. Neonates and infants treated with diazoxide should also be placed on a diuretic such as
         <a class="drug drug_pediatric" data-topicid="13148" href="/z/d/drug information/13148.html" rel="external">
          chlorothiazide
         </a>
         to reduce this risk (chlorothiazide dose 10 to 30 mg/kg/day, in two divided doses)  (
         <a class="graphic graphic_table graphicRef128296" href="/z/d/graphic/128296.html" rel="external">
          table 3
         </a>
         ). Diazoxide may also result in nausea, decreased appetite, and, in rare cases, feeding intolerance. Reports suggest that use of diazoxide in neonates may be associated with an increased risk of necrotizing enterocolitis, but additional studies are needed to better understand the association [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1980333860">
         <span class="h1">
          DIAZOXIDE-UNRESPONSIVE PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children who do not respond to
         <a class="drug drug_pediatric" data-topicid="13224" href="/z/d/drug information/13224.html" rel="external">
          diazoxide
         </a>
         , diazoxide should be discontinued and the hypoglycemia treated with intravenous (IV) dextrose, while proceeding with expedited genetic testing  (
         <a class="graphic graphic_algorithm graphicRef128425" href="/z/d/graphic/128425.html" rel="external">
          algorithm 1
         </a>
         ). An IV infusion of
         <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">
          glucagon
         </a>
         may be used if needed if the glucose infusion rate (GIR) is high and fluid overload is a concern. (See
         <a class="local">
          'Acute treatment'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H139083732">
         <span class="h2">
          Genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genetic testing is imperative for all of these children because approximately 90 percent of children with diazoxide-unresponsive HI carry a mutation in the
         <em>
          ABCC8
         </em>
         or
         <em>
          KCNJ11
         </em>
         genes, and some of these children have a focal form of HI that can be cured by surgery  (
         <a class="graphic graphic_algorithm graphicRef128425" href="/z/d/graphic/128425.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid10">
          10
         </a>
         ]. Approximately 50 to 60 percent of patients with adenosine triphosphate-sensitive potassium (K
         <sub>
          ATP
         </sub>
         )-HI (the most common genetic type) have the focal form. Referral to a center specializing in the care of HI patients should be considered for interpretation of the results and further evaluation. (See
         <a class="medical medical_review" href="/z/d/html/5810.html" rel="external">
          "Pathogenesis, clinical presentation, and diagnosis of congenital hyperinsulinism", section on 'Genetic testing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H399795378">
         <span class="h2">
          18F-DOPA PET scan
         </span>
         <span class="headingEndMark">
          —
         </span>
         The 18-fluoro-L-3,4-dihydroxyphenylalanine positron emission tomography (
         <sup>
          18
         </sup>
         F-DOPA PET) scan is used to localize focal lesions prior to surgery [
         <a href="#rid11">
          11,12
         </a>
         ]. This scan and surgery require referral to a specialized center. Surgical resection of the focal lesion is curative, so identifying patients with focal HI and localizing the lesion in the pancreas is critical to their treatment.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         – Indications for an
         <sup>
          18
         </sup>
         F-DOPA PET scan include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Genetic testing consistent with focal HI (paternally inherited recessive mutation in the
         <em>
          ABCC8
         </em>
         or
         <em>
          KCNJ11
         </em>
         genes).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Negative genetic analysis in a child with diazoxide-unresponsive HI. This includes cases in which no mutations were identified, as well as cases with variants of unknown significance in
         <em>
          ABCC8
         </em>
         or
         <em>
          KCNJ11
         </em>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Suspected Beckwith-Wiedemann syndrome and severe HI requiring pancreatectomy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <sup>
          18
         </sup>
         F-DOPA PET scans are not indicated for children who have diazoxide-responsive HI or children whose genetic testing is consistent with diffuse disease, such as biallelic recessive mutations in
         <em>
          ABCC8
         </em>
         or
         <em>
          KCNJ11
         </em>
         or mutations in
         <em>
          GCK
         </em>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Test characteristics
         </strong>
         –
         <sup>
          18
         </sup>
         F-DOPA is taken up by neuroendocrine tissue in the pancreas. The
         <sup>
          18
         </sup>
         F-DOPA PET scan should be utilized primarily to localize focal lesions in those children with suspected focal HI. In focal HI, there is increased tracer uptake in a specific area of the pancreas, corresponding to the focal lesion  (
         <a class="graphic graphic_diagnosticimage graphicRef129078" href="/z/d/graphic/129078.html" rel="external">
          image 1
         </a>
         ). In diffuse HI, there is uniform uptake of the tracer throughout the pancreas.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Studies have demonstrated that 90 to 100 percent of focal lesions are correctly localized in the pancreas [
         <a href="#rid13">
          13-15
         </a>
         ]. Development of this scan was a significant advance in the treatment of children with focal HI, allowing for accurate localization of the lesion prior to surgery and minimizing the extent of pancreas resected [
         <a href="#rid13">
          13
         </a>
         ]. Conventional imaging such as computed tomography (CT) or magnetic resonance imaging (MRI) cannot detect focal lesions, and interventional radiology techniques are invasive and only marginally effective at localizing lesions [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4055167310">
         <span class="h2">
          Patients with focal hyperinsulinism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with focal HI, as determined by
         <sup>
          18
         </sup>
         F-DOPA PET scanning, should undergo surgical resection of the lesion, which is curative [
         <a href="#rid17">
          17
         </a>
         ]. Children with focal HI should undergo treatment at a specialized HI center where a multidisciplinary team has the necessary expertise to ensure successful outcomes [
         <a href="#rid18">
          18
         </a>
         ]. In addition to the presurgical
         <sup>
          18
         </sup>
         F-DOPA PET scan, intraoperative ultrasound can be utilized to identify the focal lesion. Frozen section analysis during surgery is necessary to confirm complete resection of the focal lesion. In a large study of children with HI undergoing pancreatectomy, 97 percent of children with focal HI were cured through partial pancreatectomy and the majority required less than 50 percent of their pancreas removed [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3624249227">
         <span class="h2">
          Patients with diffuse hyperinsulinism
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with diffuse HI who do not respond to
         <a class="drug drug_pediatric" data-topicid="13224" href="/z/d/drug information/13224.html" rel="external">
          diazoxide
         </a>
         , the next step is either a trial of intensive medical therapy or referral for near-total pancreatectomy  (
         <a class="graphic graphic_algorithm graphicRef128425" href="/z/d/graphic/128425.html" rel="external">
          algorithm 1
         </a>
         ). Intensive medical therapy is generally associated with a greater risk for hypoglycemia compared with near-total pancreatectomy, as well as the risk of side effects from prolonged somatostatin analog use. However, it avoids an invasive surgical procedure and the long-term risk of diabetes and exocrine insufficiency that come with a near-total pancreatectomy. The management of these children is complex and requires careful consideration of the risks and benefits of each approach, which vary with patient characteristics (eg, a high glucose requirement [GIR] may favor the surgical approach), as well as the family's preferences and values. These decisions should be made by a team experienced in the care of HI patients, in close collaboration with the family.
        </p>
        <p class="headingAnchor" id="H784009219">
         <span class="h3">
          Intensive medical therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with diffuse HI who do not respond to
         <a class="drug drug_pediatric" data-topicid="13224" href="/z/d/drug information/13224.html" rel="external">
          diazoxide
         </a>
         , intensive medical management initially involves treatment with enteral dextrose, followed by introduction of
         <a class="drug drug_pediatric" data-topicid="12655" href="/z/d/drug information/12655.html" rel="external">
          octreotide
         </a>
         after two to three months of life. While research into new therapies is ongoing, options for medical therapy are limited  (
         <a class="graphic graphic_table graphicRef128296" href="/z/d/graphic/128296.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Enteral dextrose – A continuous enteral infusion of dextrose is administered via nasogastric or gastrostomy tube. This typically consists of a 20% solution of dextrose, with a maximum GIR of 10 mg/kg/min [
         <a href="#rid19">
          19
         </a>
         ]. This approach is preferred over continuous enteral nutrition, which can result in long-term feeding aversion. While a dextrose infusion provides a small portion of the child's caloric needs, the majority of the nutritional needs are supplied by oral feeding.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Somatostatin analogs –
         <a class="drug drug_pediatric" data-topicid="12655" href="/z/d/drug information/12655.html" rel="external">
          Octreotide
         </a>
         , a short-acting somatostatin analog, is effective for short-term management of refractory hypoglycemia, but its use is limited by tachyphylaxis and the burden of multiple subcutaneous injections per day [
         <a href="#rid20">
          20
         </a>
         ]. The dose is 2 to 20 mcg/kg/day, divided every six to eight hours (maximum total dose 500 mcg/day for an adult).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_pediatric" data-topicid="12655" href="/z/d/drug information/12655.html" rel="external">
          Octreotide
         </a>
         may be associated with fatal necrotizing enterocolitis in young infants [
         <a href="#rid21">
          21-23
         </a>
         ]. Therefore,
         <strong>
          in infants younger than eight weeks of age, octreotide should be used with extreme caution and only if there are no other risk factors
         </strong>
         for necrotizing enterocolitis. Other potential adverse effects include gallstones, aminotransferase elevations, malabsorption, and hypothyroidism.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="10184" href="/z/d/drug information/10184.html" rel="external">
          Lanreotide
         </a>
         is a long-acting somatostatin analog administered as a monthly injection [
         <a href="#rid24">
          24
         </a>
         ]. The dosing range is 60 to 120 mg every 28 days. Given limited safety data, lanreotide is typically reserved for children aged one year or older.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The side effect profiles of
         <a class="drug drug_pediatric" data-topicid="12655" href="/z/d/drug information/12655.html" rel="external">
          octreotide
         </a>
         and
         <a class="drug drug_general" data-topicid="10184" href="/z/d/drug information/10184.html" rel="external">
          lanreotide
         </a>
         are similar. These are second-line agents in the treatment of HI and should only be considered for use in children who are not responsive to
         <a class="drug drug_pediatric" data-topicid="13224" href="/z/d/drug information/13224.html" rel="external">
          diazoxide
         </a>
         .
        </p>
        <p>
        </p>
        <p>
         Other medications have been trialed as treatment for HI with limited success. Steroids have no efficacy in HI and expose children to unnecessary side effects. They should not be used as a treatment for HI. Calcium channel blockers, such as
         <a class="drug drug_pediatric" data-topicid="12643" href="/z/d/drug information/12643.html" rel="external">
          nifedipine
         </a>
         , have also been trialed without success [
         <a href="#rid25">
          25
         </a>
         ]. A mammalian (mechanistic) target of rapamycin (mTOR) inhibitor,
         <a class="drug drug_pediatric" data-topicid="12761" href="/z/d/drug information/12761.html" rel="external">
          sirolimus
         </a>
         , was initially reported as an effective treatment, but subsequent studies failed to show efficacy [
         <a href="#rid26">
          26,27
         </a>
         ]. Sirolimus is not recommended to treat children with HI, due to the risk of immune compromise [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H387152790">
         <span class="h3">
          Near-total pancreatectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with diffuse HI who fail medical therapy undergo a near-total (98 percent) pancreatectomy and gastrostomy tube placement [
         <a href="#rid17">
          17
         </a>
         ]. This surgery is palliative only, and the majority of children have ongoing hypoglycemia, albeit less severe [
         <a href="#rid29">
          29,30
         </a>
         ]. The gastrostomy tube helps to facilitate enteral administration of dextrose postoperatively. Long-term outcomes for patients who undergo near-total pancreatectomies, including development of diabetes, are discussed below.
        </p>
        <p class="headingAnchor" id="H3280968013">
         <span class="h1">
          OUTCOMES
         </span>
        </p>
        <p class="headingAnchor" id="H799110278">
         <span class="h2">
          Neurocognitive outcomes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Brain damage is a well-known consequence of hypoglycemia. In children with HI, the risk is particularly high due to the severity of the hypoglycemia as well as suppression of ketone production, a critical alternative fuel for the brain. The prevalence of neurodevelopmental deficits in children with HI is 26 to 48 percent, and the prevalence of epilepsy is 13 to 29 percent [
         <a href="#rid31">
          31-34
         </a>
         ]. Behavioral problems, speech delays, and learning disabilities are the most common neurodevelopmental abnormalities reported [
         <a href="#rid32">
          32
         </a>
         ]. Despite the difference in long-term hypoglycemia outcomes, children with diffuse and focal HI have similar rates of developmental abnormalities. Children with transient forms of HI are also at risk of abnormal development. The proportion of developmental delays in children with transient HI is not statistically different from those with the congenital forms [
         <a href="#rid35">
          35,36
         </a>
         ].
        </p>
        <p>
         Despite significant advances in prompt diagnosis and management of HI, the prevalence of neurodevelopmental deficits has not decreased over time [
         <a href="#rid32">
          32
         </a>
         ]. Therefore, early identification and treatment of developmental issues are essential. All children with HI, regardless of type or treatment, should have periodic developmental assessments and, if an abnormality is found, be quickly referred for therapy  (
         <a class="graphic graphic_table graphicRef128297" href="/z/d/graphic/128297.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H920150258">
         <span class="h2">
          Postpancreatectomy outcomes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children who undergo near-total pancreatectomy are at high risk of diabetes and exocrine insufficiency. In a study of 105 children with HI who underwent pancreatectomy, 100 percent of patients with the diffuse form had documented hyperglycemia at age 13 years and 91 percent required insulin at age 14 years [
         <a href="#rid30">
          30
         </a>
         ]. The median age of diabetes diagnosis is approximately eight years [
         <a href="#rid30">
          30-32
         </a>
         ]. Children with postpancreatectomy diabetes have lower insulin requirements than those with type 1 diabetes, although hemoglobin A1c levels are compatible between the two groups [
         <a href="#rid37">
          37
         </a>
         ]. The development of exocrine insufficiency has not been extensively examined yet. One study of 45 children who underwent near-total pancreatectomy for diffuse HI found that 72 percent had an undetectable fecal elastase and 49 percent had clinical symptoms consistent with exocrine insufficiency [
         <a href="#rid38">
          38
         </a>
         ]. Screening for diabetes and exocrine insufficiency is recommended for any child who has undergone a near-total pancreatectomy.
        </p>
        <p class="headingAnchor" id="H2709065367">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117462.html" rel="external">
          "Society guideline links: Hypoglycemia in infants and children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical importance and goals
         </strong>
         – Hyperinsulinism (HI) is associated with a high risk of neurologic damage due to the severity of the hypoglycemia and the suppression of ketones, a critical alternative fuel for the brain. To mitigate the risk of long-term neurologic sequela, principles of management include early identification of patients and initiation of appropriate therapy to maintain euglycemia (plasma glucose ≥70 mg/dL). (See
         <a class="local">
          'Treatment goals'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diazoxide-responsive patients
         </strong>
         – Management of HI is summarized in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef128425" href="/z/d/graphic/128425.html" rel="external">
          algorithm 1
         </a>
         ). The first step is a therapeutic trial of
         <a class="drug drug_pediatric" data-topicid="13224" href="/z/d/drug information/13224.html" rel="external">
          diazoxide
         </a>
         , which is an adenosine triphosphate-sensitive potassium
         <sub>
         </sub>
         (K
         <sub>
          ATP
         </sub>
         ) channel agonist  (
         <a class="graphic graphic_table graphicRef128296" href="/z/d/graphic/128296.html" rel="external">
          table 3
         </a>
         ). Diazoxide should be continued in those who respond well to this treatment, ie, children who are able to maintain euglycemia on an age-appropriate diet and while fasting. (See
         <a class="local">
          'Diazoxide trial'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diazoxide-unresponsive patients
         </strong>
         – Children who do not respond to
         <a class="drug drug_pediatric" data-topicid="13224" href="/z/d/drug information/13224.html" rel="external">
          diazoxide
         </a>
         may have focal HI, which can often be cured by surgery. Next steps are  (
         <a class="graphic graphic_algorithm graphicRef128425" href="/z/d/graphic/128425.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Genetic testing
         </strong>
         – To evaluate for focal HI, perform expedited genetic analysis of the
         <em>
          ABCC8
         </em>
         or
         <em>
          KCNJ11
         </em>
         genes, using a laboratory that can provide results within four to seven days. Mutations in these genes are responsible for 90 percent of cases of diazoxide-unresponsive HI. A paternally inherited recessive mutation in
         <em>
          ABCC8
         </em>
         or
         <em>
          KCNJ11
         </em>
         has a 94 percent positive predictive value for focal HI. (See
         <a class="local">
          'Genetic testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          <sup>
           18
          </sup>
         </strong>
         <strong>
          F-DOPA PET (selected patients)
         </strong>
         – For all children with a paternally inherited recessive mutation in the
         <em>
          ABCC8
         </em>
         or
         <em>
          KCNJ11
         </em>
         genes or those with a negative genetic analysis (but not those with biallelic recessive mutations in
         <em>
          ABCC8
         </em>
         or
         <em>
          KCNJ11
         </em>
         or mutations in
         <em>
          GCK
         </em>
         ), perform 18-fluoro-L-3,4-dihydroxyphenylalanine positron emission tomography (
         <sup>
          18
         </sup>
         F-DOPA PET). The purpose of this scan is to localize the lesion prior to surgery  (
         <a class="graphic graphic_diagnosticimage graphicRef129078" href="/z/d/graphic/129078.html" rel="external">
          image 1
         </a>
         ). This scan is also indicated for patients with suspected Beckwith-Wiedemann syndrome and severe HI requiring pancreatectomy. (See
         <a class="local">
          '18F-DOPA PET scan'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients with focal HI
         </strong>
         – Surgical intervention is indicated for children with focal HI who fail medical management  (
         <a class="graphic graphic_algorithm graphicRef128425" href="/z/d/graphic/128425.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid17">
          17
         </a>
         ]. Resection of the focal lesion via partial pancreatectomy is curative for children with focal disease. (See
         <a class="local">
          'Patients with focal hyperinsulinism'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients with diffuse HI
         </strong>
         – For children with diffuse HI who do not respond to
         <a class="drug drug_pediatric" data-topicid="13224" href="/z/d/drug information/13224.html" rel="external">
          diazoxide
         </a>
         , the next step is either a trial of intensive medical therapy or referral for a near-total pancreatectomy  (
         <a class="graphic graphic_algorithm graphicRef128425" href="/z/d/graphic/128425.html" rel="external">
          algorithm 1
         </a>
         ). Deciding between the medical and surgical approaches requires careful consideration of their risks and benefits, as well as close collaboration between the family and a team specializing in the care of children with HI. (See
         <a class="local">
          'Patients with diffuse hyperinsulinism'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Intensive medical therapy consists of continuous dextrose administration via gastrostomy tube, combined with a somatostatin analog (after age two months). This approach is generally associated with a greater risk for hypoglycemia compared with near-total pancreatectomy, as well as the risk of side effects from prolonged somatostatin analog use  (
         <a class="graphic graphic_table graphicRef128296" href="/z/d/graphic/128296.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Intensive medical therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         After near-total pancreatectomy, the majority of children will continue to have hypoglycemia, albeit less severe, and all children will eventually develop insulin-dependent diabetes [
         <a href="#rid30">
          30
         </a>
         ]. (See
         <a class="local">
          'Postpancreatectomy outcomes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurocognitive outcomes
         </strong>
         – Despite advances in the field, the risk of neurocognitive abnormalities in children with HI remains high. Developmental deficits occur in 26 to 48 percent of individuals with HI, and 13 to 26 percent have epilepsy [
         <a href="#rid31">
          31-34
         </a>
         ]. This elevated risk occurs in both transient and monogenic forms [
         <a href="#rid35">
          35
         </a>
         ]. Early identification and treatment of developmental issues are essential. All children with HI, regardless of type or treatment, should have periodic developmental assessments  (
         <a class="graphic graphic_table graphicRef128060" href="/z/d/graphic/128060.html" rel="external">
          table 2
         </a>
         ). If an abnormality is found, the child should be promptly referred for therapy. (See
         <a class="local">
          'Neurocognitive outcomes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4176285776">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Agneta Sunehag, MD, PhD, and Morey W Haymond, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Lord K, De Leon-Crutchlow DD. Neurodevelopmental outcomes. In: Congenital Hyperinsulinism: A Practical Guide to Diagnosis and Management, De Leon-Crutchlow DD, Stanley CA (Eds), Humana Press, 2019. p.155.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hawkes CP, Lado JJ, Givler S, De Leon DD. The Effect of Continuous Intravenous Glucagon on Glucose Requirements in Infants with Congenital Hyperinsulinism. JIMD Rep 2019; 45:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hawkes CP, De Leon DD, Rickels MR. Novel Preparations of Glucagon for the Prevention and Treatment of Hypoglycemia. Curr Diab Rep 2019; 19:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Worth C, Hall C, Wilson S, et al. Delayed Resolution of Feeding Problems in Patients With Congenital Hyperinsulinism. Front Endocrinol (Lausanne) 2020; 11:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DRASH A, WOLFF F. DRUG THERAPY IN LEUCINE-SENSITIVE HYPOGLYCEMIA. Metabolism 1964; 13:487.
          </a>
         </li>
         <li class="breakAll">
          Yau D, Stanley CA. Diazoxide-responsive forms of congenital hyperinsulinism. In: Congenital Hyperinsulinism: A Practical Guide to Diagnosis and Management, De Leon-Crutchlow DD, Stanley CA (Eds), Humana Press, 2019. p.15.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrera A, Vajravelu ME, Givler S, et al. Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide. J Clin Endocrinol Metab 2018; 103:4365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prado LA, Castro M, Weisz DE, et al. Necrotising enterocolitis in newborns receiving diazoxide. Arch Dis Child Fetal Neonatal Ed 2021; 106:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keyes ML, Healy H, Sparger KA, et al. Necrotizing Enterocolitis in Neonates With Hyperinsulinemic Hypoglycemia Treated With Diazoxide. Pediatrics 2021; 147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Snider KE, Becker S, Boyajian L, et al. Genotype and phenotype correlations in 417 children with congenital hyperinsulinism. J Clin Endocrinol Metab 2013; 98:E355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otonkoski T, Näntö-Salonen K, Seppänen M, et al. Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography. Diabetes 2006; 55:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ribeiro MJ, De Lonlay P, Delzescaux T, et al. Characterization of hyperinsulinism in infancy assessed with PET and 18F-fluoro-L-DOPA. J Nucl Med 2005; 46:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hardy OT, Hernandez-Pampaloni M, Saffer JR, et al. Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. J Clin Endocrinol Metab 2007; 92:4706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laje P, States LJ, Zhuang H, et al. Accuracy of PET/CT Scan in the diagnosis of the focal form of congenital hyperinsulinism. J Pediatr Surg 2013; 48:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barthlen W, Blankenstein O, Mau H, et al. Evaluation of [18F]fluoro-L-DOPA positron emission tomography-computed tomography for surgery in focal congenital hyperinsulinism. J Clin Endocrinol Metab 2008; 93:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stanley CA, Thornton PS, Ganguly A, et al. Preoperative evaluation of infants with focal or diffuse congenital hyperinsulinism by intravenous acute insulin response tests and selective pancreatic arterial calcium stimulation. J Clin Endocrinol Metab 2004; 89:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adzick NS, De Leon DD, States LJ, et al. Surgical treatment of congenital hyperinsulinism: Results from 500 pancreatectomies in neonates and children. J Pediatr Surg 2019; 54:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palladino AA, Stanley CA. A specialized team approach to diagnosis and medical versus surgical treatment of infants with congenital hyperinsulinism. Semin Pediatr Surg 2011; 20:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vajravelu ME, Congdon M, Mitteer L, et al. Continuous Intragastric Dextrose: A Therapeutic Option for Refractory Hypoglycemia in Congenital Hyperinsulinism. Horm Res Paediatr 2019; 91:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirsch HJ, Loo S, Evans N, et al. Hypoglycemia of infancy and nesidioblastosis. Studies with somatostatin. N Engl J Med 1977; 296:1323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laje P, Halaby L, Adzick NS, Stanley CA. Necrotizing enterocolitis in neonates receiving octreotide for the management of congenital hyperinsulinism. Pediatr Diabetes 2010; 11:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hawkes CP, Adzick NS, Palladino AA, De León DD. Late Presentation of Fulminant Necrotizing Enterocolitis in a Child with Hyperinsulinism on Octreotide Therapy. Horm Res Paediatr 2016; 86:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McMahon AW, Wharton GT, Thornton P, De Leon DD. Octreotide use and safety in infants with hyperinsulinism. Pharmacoepidemiol Drug Saf 2017; 26:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Modan-Moses D, Koren I, Mazor-Aronovitch K, et al. Treatment of congenital hyperinsulinism with lanreotide acetate (Somatuline Autogel). J Clin Endocrinol Metab 2011; 96:2312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Güemes M, Shah P, Silvera S, et al. Assessment of Nifedipine Therapy in Hyperinsulinemic Hypoglycemia due to Mutations in the ABCC8 Gene. J Clin Endocrinol Metab 2017; 102:822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Senniappan S, Alexandrescu S, Tatevian N, et al. Sirolimus therapy in infants with severe hyperinsulinemic hypoglycemia. N Engl J Med 2014; 370:1131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szymanowski M, Estebanez MS, Padidela R, et al. mTOR Inhibitors for the Treatment of Severe Congenital Hyperinsulinism: Perspectives on Limited Therapeutic Success. J Clin Endocrinol Metab 2016; 101:4719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banerjee I, De Leon D, Dunne MJ. Extreme caution on the use of sirolimus for the congenital hyperinsulinism in infancy patient. Orphanet J Rare Dis 2017; 12:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lord K, Dzata E, Snider KE, et al. Clinical presentation and management of children with diffuse and focal hyperinsulinism: a review of 223 cases. J Clin Endocrinol Metab 2013; 98:E1786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beltrand J, Caquard M, Arnoux JB, et al. Glucose metabolism in 105 children and adolescents after pancreatectomy for congenital hyperinsulinism. Diabetes Care 2012; 35:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menni F, de Lonlay P, Sevin C, et al. Neurologic outcomes of 90 neonates and infants with persistent hyperinsulinemic hypoglycemia. Pediatrics 2001; 107:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lord K, Radcliffe J, Gallagher PR, et al. High Risk of Diabetes and Neurobehavioral Deficits in Individuals With Surgically Treated Hyperinsulinism. J Clin Endocrinol Metab 2015; 100:4133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jack MM, Greer RM, Thomsett MJ, et al. The outcome in Australian children with hyperinsulinism of infancy: early extensive surgery in severe cases lowers risk of diabetes. Clin Endocrinol (Oxf) 2003; 58:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ludwig A, Enke S, Heindorf J, et al. Formal Neurocognitive Testing in 60 Patients with Congenital Hyperinsulinism. Horm Res Paediatr 2018; 89:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avatapalle HB, Banerjee I, Shah S, et al. Abnormal Neurodevelopmental Outcomes are Common in Children with Transient Congenital Hyperinsulinism. Front Endocrinol (Lausanne) 2013; 4:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinkrauss L, Lipman TH, Hendell CD, et al. Effects of hypoglycemia on developmental outcome in children with congenital hyperinsulinism. J Pediatr Nurs 2005; 20:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Welters A, Meissner T, Grulich-Henn J, et al. Characterization of diabetes following pancreatic surgery in patients with congenital hyperinsulinism. Orphanet J Rare Dis 2018; 13:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arya VB, Senniappan S, Demirbilek H, et al. Pancreatic endocrine and exocrine function in children following near-total pancreatectomy for diffuse congenital hyperinsulinism. PLoS One 2014; 9:e98054.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5851 Version 32.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Lord K, De Leon-Crutchlow DD. Neurodevelopmental outcomes. In: Congenital Hyperinsulinism: A Practical Guide to Diagnosis and Management, De Leon-Crutchlow DD, Stanley CA (Eds), Humana Press, 2019. p.155.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30311139" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The Effect of Continuous Intravenous Glucagon on Glucose Requirements in Infants with Congenital Hyperinsulinism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31493043" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Novel Preparations of Glucagon for the Prevention and Treatment of Hypoglycemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32256453" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Delayed Resolution of Feeding Problems in Patients With Congenital Hyperinsulinism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14193979" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : DRUG THERAPY IN LEUCINE-SENSITIVE HYPOGLYCEMIA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14193979" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : DRUG THERAPY IN LEUCINE-SENSITIVE HYPOGLYCEMIA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30247666" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33172872" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Necrotising enterocolitis in newborns receiving diazoxide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33483452" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Necrotizing Enterocolitis in Neonates With Hyperinsulinemic Hypoglycemia Treated With Diazoxide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23275527" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Genotype and phenotype correlations in 417 children with congenital hyperinsulinism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16380471" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15809476" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Characterization of hyperinsulinism in infancy assessed with PET and 18F-fluoro-L-DOPA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17895314" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23414871" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Accuracy of PET/CT Scan in the diagnosis of the focal form of congenital hyperinsulinism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18073294" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Evaluation of [18F]fluoro-L-DOPA positron emission tomography-computed tomography for surgery in focal congenital hyperinsulinism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14715863" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Preoperative evaluation of infants with focal or diffuse congenital hyperinsulinism by intravenous acute insulin response tests and selective pancreatic arterial calcium stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30343978" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Surgical treatment of congenital hyperinsulinism: Results from 500 pancreatectomies in neonates and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21186002" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A specialized team approach to diagnosis and medical versus surgical treatment of infants with congenital hyperinsulinism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30086540" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Continuous Intragastric Dextrose: A Therapeutic Option for Refractory Hypoglycemia in Congenital Hyperinsulinism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/193007" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Hypoglycemia of infancy and nesidioblastosis. Studies with somatostatin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19558634" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Necrotizing enterocolitis in neonates receiving octreotide for the management of congenital hyperinsulinism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26867223" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Late Presentation of Fulminant Necrotizing Enterocolitis in a Child with Hyperinsulinism on Octreotide Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27910218" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Octreotide use and safety in infants with hyperinsulinism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21697252" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Treatment of congenital hyperinsulinism with lanreotide acetate (Somatuline Autogel).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27898257" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Assessment of Nifedipine Therapy in Hyperinsulinemic Hypoglycemia due to Mutations in the ABCC8 Gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24645945" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Sirolimus therapy in infants with severe hyperinsulinemic hypoglycemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27691052" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : mTOR Inhibitors for the Treatment of Severe Congenital Hyperinsulinism: Perspectives on Limited Therapeutic Success.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28410602" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Extreme caution on the use of sirolimus for the congenital hyperinsulinism in infancy patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24057290" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Clinical presentation and management of children with diffuse and focal hyperinsulinism: a review of 223 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22190679" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Glucose metabolism in 105 children and adolescents after pancreatectomy for congenital hyperinsulinism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11230585" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Neurologic outcomes of 90 neonates and infants with persistent hyperinsulinemic hypoglycemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26327482" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : High Risk of Diabetes and Neurobehavioral Deficits in Individuals With Surgically Treated Hyperinsulinism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12608942" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The outcome in Australian children with hyperinsulinism of infancy: early extensive surgery in severe cases lowers risk of diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29151084" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Formal Neurocognitive Testing in 60 Patients with Congenital Hyperinsulinism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23730298" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Abnormal Neurodevelopmental Outcomes are Common in Children with Transient Congenital Hyperinsulinism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15815570" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Effects of hypoglycemia on developmental outcome in children with congenital hyperinsulinism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30577875" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Characterization of diabetes following pancreatic surgery in patients with congenital hyperinsulinism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24840042" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Pancreatic endocrine and exocrine function in children following near-total pancreatectomy for diffuse congenital hyperinsulinism.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
